🔎 Trials Near Me

Home › Cancro del polmone non a piccole cellule › Indiana

Studi clinici su Cancro del polmone non a piccole cellule nello stato di Indiana

49 studi su Cancro del polmone non a piccole cellule cercano partecipanti presso sedi nello stato di Indiana.

Città nello stato di Indiana

Testo ufficiale dello studio (inglese)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Northwest Cancer Center - Crown Point, Crown Point
  • Northwest Oncology LLC, Dyer
  • Parkview Regional Medical Center, Fort Wayne
  • e altri 7
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  • Franciscan Health ( Site 0219), Indianapolis
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06623422

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • IU Simon Cancer Center, Indianapolis
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06465069

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #4, Indianapolis
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT05176483

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

  • Northwest Cancer Center - Crown Point, Crown Point
  • Northwest Oncology LLC, Dyer
  • Saint Mary Medical Center, Hobart
  • e altri 4
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07388524

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  • Parkview Research Center /ID# 277651, Fort Wayne
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07155187

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

  • Indiana University Simon Comprehensive Cancer Center, Indianapolis
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06625775

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  • Indiana University Health Arnett Cancer Center ( Site 0116), Lafayette
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07190248

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • IU Health West Hospital, Avon
  • IU Health North Hospital, Carmel
  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
  • e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06498635

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  • Fort Wayne Medical Oncology and Hematology, Fort Wayne
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07361497

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  • Northwest Cancer Centers, P.C., Dyer
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07361510

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

  • Parkview Comprehensive Cancer Center /ID# 271879, Fort Wayne
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT06772623

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  • Parkview Research Center at Parkview Regional Medical Center ( Site 0089), Fort Wayne
  • Indiana University Health Arnett Cancer Center ( Site 0076), Lafayette
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06312137

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Community Health Network, Inc, Indianapolis
  • Community Health Network, Inc., Indianapolis
  • Community Health Network, Inc., Indianapolis
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07222566

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Fort Wayne Medical Oncology and Hematology, Fort Wayne
  • Investigative Clinical Research of Indiana, LLC, Noblesville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06667076

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Franciscan Health, Munster
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07154290

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
  • Franciscan Health, Indianapolis
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06890598

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  • Research Site, Noblesville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT06357533

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne
  • Indiana University Health University Hospital, Indianapolis
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06712316

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • Community Health Network, Indianapolis
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06128551

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

  • Indiana University (IU) Health - Multi-D Oncology Clinic, Indianapolis
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07488676

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  • Northwest Cancer Centers, P.C., Dyer
  • Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06875310

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  • Research Site, Fort Wayne
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  • Clinical Study Site, Indianapolis
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT06767514

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • Goshen Center for Cancer Care, Goshen
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT04613596

Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 set 2026 · NCT07761910

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
  • Franciscan Health, Indianapolis
  • e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06119581

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

  • Community Health Network, Indianapolis
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT07027514

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

  • Research Site, Fort Wayne
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 26 ago 2026 · NCT06350097

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

  • Community Health Network, Indianapolis
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT06586515

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

  • Fort Wayne Medical Oncology and Hematology, Fort Wayne
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 lug 2026 · NCT06150664

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • UChicago Medicine - Northwest Indiana, Crown Point
  • Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
  • Community Health Network, Inc, Indianapolis
  • e altri 3
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT04389632

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  • Parkview Packnett Family Cancer Institute, Fort Wayne
  • Franciscan Health Indianapolis, Indianapolis
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 giu 2026 · NCT06216301

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

  • Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne
  • Community Health Network, Inc. /ID# 243011, Indianapolis
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 giu 2026 · NCT05005403

A Study of LY4175408 in Participants With Advanced Cancer

  • Community Health Network, Indianapolis
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 giu 2026 · NCT07046923

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 mag 2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
In reclutamentoFase 2
18 Minutes · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT06031688

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT04317534

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
  • Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT06616584

A Study of VET3-TGI in Patients With Solid Tumors

  • Community Health Network, Indianapolis
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 apr 2026 · NCT06444815

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.